Thromboprophylaxis with intermediate-dose tinzaparin in patients with active cancer and high thrombotic burden was associated with a 2.06% rate of thrombotic events and a 2.6% rate of bleeding events.
Cohort (n=291)
No
Does tinzaparin prevent thrombotic events in ambulatory patients with active cancer undergoing surgical and/or chemotherapy treatment?
Thromboprophylaxis with intermediate-dose tinzaparin is safe and effective in ambulatory patients with active cancer undergoing surgical and/or chemotherapy treatment.
BACKGROUND: Patients with active cancer have a 4-sevenfold increased risk for venous thromboembolism (VTE) especially during systematic anticancer treatment. Simultaneously, surgery is an additional risk factor. METHODS: The Metaxas's Hospital THromboprophylaxis program in Oncological 6 of them were minor. CONCLUSIONS: Thromboprophylaxis with LMWH in patients with active cancer and high thrombotic burden was safe and effective. Intermediate dose of tinzaparin seems to be an appropriate agent for cancer-associated thromboprophylaxis management. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT04248348.
Xynogalos et al. (Thu,) conducted a cohort in Active cancer with high thrombotic risk (n=291). Tinzaparin was evaluated on Thrombotic events (95% CI 0.76-4.43). Thromboprophylaxis with intermediate-dose tinzaparin in patients with active cancer and high thrombotic burden was associated with a 2.06% rate of thrombotic events and a 2.6% rate of bleeding events.